Pembrolizumab + axitinib
Checked 2026-09-09
Untreated advanced clear-cell RCC, any IMDC risk
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Axitinib Small-molecule kinase inhibitor (VEGFR) | 5 mg twice daily (titrate to 7 then 10 mg) | Oral | D1-21 |
Cycles
pembrolizumab up to 35 cycles; axitinib until progression
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Hepatitis on the combination can be either drug: hold both, then rechallenge axitinib first.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Nivolumab + ipilimumab (RCC)
Untreated advanced clear-cell RCC, IMDC intermediate or poor risk
every 21 days × 4
Sunitinib 4/2
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
every 42 days